Pharmaceutical Technology

JULY 12, 2022

The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

European Pharmaceutical Review

AUGUST 22, 2023

Between 2023-2028, the global bioprocess containers market is anticipated to see strong growth. This can therefore lead to inefficiencies and additional costs. A market report by Research and Markets considers this to be mainly due to the higher demand for automation and machine learning in the biopharmaceutical industry.

Marketing 98

Marketing Manufacturing Leads Pharmaceutical 98

European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

Marketing 98

Marketing Sales Physicians Patients 98

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5

Sales 52

Sales Leads Competition Medicine 52

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators and cell therapies lead the way in the pre-registration stage, which features no cancer vaccines and oncolytic virus-focused therapies, she added.

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

Pharmaceutical Technology

JANUARY 25, 2023

Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022. Despite this, Spikevax vaccine market share is expected to decline from 30% in 2022 to just 16% by the end of 2028.

Competition 59

Competition Sales Marketing Leads 59

European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

Biopharma 98

Biopharma Marketing Sales Medicine 98

Sales Talent

FEBRUARY 7, 2020

This pressure is leading to increased base salaries. jobs by 2028 , there should be an even bigger shortfall between the number of open jobs and available workers. With sales job openings increasing and the number of available unemployed sales professionals decreasing, employers find themselves fighting for the same talent.

Sales 130

Sales B2B Sales Recruitment Marketing 130

Pharmaceutical Technology

NOVEMBER 8, 2022

These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. This will form the foundation to establish a leading international ophthalmology franchise, expediting work for addressing the unmet needs in the area of ophthalmic diseases. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration 59

Food and Drug Administration Leads Food Pharma 59

PM360

SEPTEMBER 21, 2023

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Some stakeholders have expressed concern that negotiation could lead to a reduction in drug innovation. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Johnson & Johnson maintained its leading position despite a decline of 12.8%

Marketing 52

Marketing Sales Pharma Leads 52

Medico Reach

OCTOBER 17, 2022

million by 2028. However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

European Pharmaceutical Review

FEBRUARY 14, 2023

On the importance of the vaccine, she shared: “Respiratory diseases are a major public health priority given they… are a leading cause of hospitalisation.” According to a recent market research report , a total of five marketed mRNA non-vaccine products will generate over $2 billion by 2028.

Food and Drug Administration 105

Food and Drug Administration Medicine Safety Consulting 105

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

European Pharmaceutical Review

NOVEMBER 1, 2023

It is one of the leading causes of death associated with AMR globally. Using this approach, our lead programme – RVX 001, a protein-based vaccine against invasive pneumococcal disease – has been designed with antigens common to all pneumococcus serotypes. Bacterial vaccines in clinical and preclinical development 2021 [Internet].

Safety 115

Safety Marketing Manufacturing Leads 115

European Pharmaceutical Review

AUGUST 15, 2022

According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. Reuters reported that GSK had acknowledged the fall in supply and said it was pursuing plans to address the deficit.

Manufacturing 98

Manufacturing Pharma Leads Pharmaceutical 98

European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028.

Safety 98

Safety Pharmacology Training Manufacturing 98

Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

JANUARY 5, 2023

Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Address mental health early: Burnout is common amongst professionals in the pharmaceutical industry and leads to high turnover.

Pharmaceutical 90

Pharmaceutical Recruitment Training Education 90

European Pharmaceutical Review

OCTOBER 12, 2023

Subject to planning permission, the site is expected to be opened by 2028. At the time of the announcement, Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, shared that the Novo Nordisk Foundation Cellerator has potential to be “a leading player in Europe and a model for similar facilities around the world”.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

European Pharmaceutical Review

JUNE 27, 2022

According to the ClinicalTrials.gov trial registry, as of April 2022 3 there were 231 bsAbs in clinical trials and a recent industry report 4 predicts the global market revenue for these products will exceed $20 billion by 2028. Figure 1: Example of bi-specific formats. Tools such as the Lonza High?Throughput Nat Rev Drug Discov.

Recruitment 98

Recruitment Manufacturing Media Leads 98

pharmaphorum

JULY 7, 2022

The latest report – in the Wall Street Journal – says that “advanced talks” are underway that could lead to a $200-plus per share offer that would value Seagen at a massive $40 billion, $10 billion more than earlier estimates.

Marketing 52

Marketing Pharma Sales Medicine 52

pharmaphorum

AUGUST 2, 2022

Merck is well-positioned to understand the importance of oncology and the potential for sales, with its lead product, Keytruda (pembrolizumab), being the second best-selling drug worldwide in 2021, after earning $17.2 billion in revenue last year.

Marketing 98

Marketing Prospecting Sales Pharma 98

PM360

JUNE 24, 2024

By analyzing, sifting, and sorting patient data, AI tools enable healthcare providers to significantly improve their interactions with patients, ultimately leading to enhanced satisfaction and better healthcare outcomes. million by 2028. Ultimately, these advancements lead to enhanced patient care and outcomes.

Physicians 59

Physicians Patients Healthcare Provider Healthcare 59

Medico Reach

MARCH 24, 2023

billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 Proper research and investment in this field can lead to treating the disease efficiently. The Cancer Immunotherapy Market Size is estimated to reach $152.6 It is further expected to reach USD 14,505 million in 2030.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 Proper research and investment in this field can lead to treating the disease efficiently. The Cancer Immunotherapy Market Size is estimated to reach $152.6 It is further expected to reach USD 14,505 million in 2030.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. A lack of good antigens to target in AML is widely believed to have caused this dearth of effective cell therapies.

Marketing 52

Marketing Sales FDA Management 52

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

Nixon Gwilt Law

MAY 26, 2023

CMS and other payors do not currently pay for these codes , but billing practitioners should continue to submit claims including the codes to provide necessary information that will hopefully lead to more reimbursement opportunities for VR in the future. Telehealth.

Healthcare 119

Healthcare Healthcare Marketing Healthcare Provider 119

MedTechVets

OCTOBER 27, 2023

billion in 2028.” We enjoy leading it in our core but at the same time, companies need to see that we are learners, followers, and committed to the end result.” “The Medical Device field is projected to grow from $455.34 billion in 2021 to $657.98

Medical 59

Medical Ethics Recruitment Marketing 59

Medico Reach

JUNE 2, 2022

It also has products from other leading manufacturers. Brasseler USA is one of the leading dental instrumentation companies popular for restorative, orthodontic, endodontic, and oral surgery equipment. It’s one of the leading manufacturers in North America and has catered to the needs of numerous dental clinics and doctors.

Marketing 52

Marketing Manufacturing Distribution Leads 52

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%). Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

European Pharmaceutical Review

NOVEMBER 30, 2023

NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

OCTOBER 10, 2022

Because it was a new service, people were concerned that it was a scam or just another flyer to put in the bin,” explains Jane Derbyshire, lung project lead for RM Partners West London Cancer Alliance. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.

Patients 98

Patients Pharma Media Training 98